Search

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

The HARMONY project: learning to work in BIG (DATA) teams

The HARMONY project: learning to work in BIG (DATA) teams

By Anna Kabanova PhD, YoungEHA committee member

On 26 and 27 September 2019 several YoungEHA members, including myself, had the chance to participate in the 4th General Assembly of the HARMONY Alliance…

Read more

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference on Bone Marrow Failure and Leukaemia Predisposition Syndromes

Date: November 15-17, 2024
Location: Paris, France

Chairpersons: Carmem Bonfim, Tim Brümmendorf, Antonio Risitano, Sharon Savage
Scientific Committee: Beatrice Drexler, Carlo Dufour, Morag Griffin, Régis Peffault de Latour

With the support of the Severe Aplastic…

Read more

EHA policy on double awarding

EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.

Read more

Specialized Working Groups

EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.

Read more

Report on first EHA-SWG Scientific Meeting

The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.

Read more

Chairs and Members

Chair and affiliation:
Willem E.

Read more

Acute Lymphocytic Leukemia: impressive results with the monoclonal antibody blinatumomab

The Phase 2 dose-ranging study MT103-206 evaluated the efficacy, safety and tolerability of blinatumomab in adult patients with B-precursor Acute Lymphoblastic Leukemia who had relapsed following treatment with standard front-line chemotherapy or allogeneic stem cell transplant.

Read more